Press Announcements > FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder

Press Announcements > FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder



FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder

The U.S. Food and Drug Administration today approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days. Continue reading.